Pharmacokinetics of pazopanib administered in combination with bevacizumab View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-06

AUTHORS

Diane-Charlotte Imbs, Sylvie Négrier, Philippe Cassier, Antoine Hollebecque, Andrea Varga, Ellen Blanc, Thierry Lafont, Bernard Escudier, Jean-Charles Soria, David Pérol, Etienne Chatelut

ABSTRACT

A combination of monoclonal antibody that binds and inhibits effects induced by vascular endothelial growth factor and tyrosine kinase inhibitor of vascular endothelial growth factor receptor represents a promising concept to block pathological angiogenesis completely. A phase I study combining daily oral pazopanib and bevacizumab (given iv every 2 weeks) was performed in order to determine the maximum tolerated dose of the two drugs in combination. Pazopanib pharmacokinetics were evaluated to compare pharmacokinetic parameters given alone and those observed on the day of the bevacizumab administration. Plasma pazopanib concentrations were obtained in 25 patients treated at two dose levels (400 or 600 mg) at Day 1 (given alone) and Day 15 (the day of the 7.5 mg/kg bevacizumab infusion), and analyzed using the NONMEM program. The apparent oral clearance (CL/F, mean value of 0.60 L/h) presented an inter-individual variability of 40 %, and an inter-occasion of 27 %. A modest but statistically significant decrease in CL/F was observed from Day 1 to Day 15 (-16.4, 95 % confidence interval of -8.5 to -27.2 %). However, trough pazopanib concentrations observed at Day 16 (24 h after the bevacizumab iv infusion) were not significantly higher than those observed just before the beginning of the bevacizumab iv infusion, suggesting that the pharmacokinetic change between Day 1 and Day 15 was not due to an interaction of bevacizumab. Overall, the mean observed concentrations at the maximum tolerated pazopanib dose (600 mg) at both Day 1 and Day 15 were higher than those observed at 800 mg once daily level (corresponding to the recommended dose when given alone) during the first-in-man phase 1 study of pazopanib in monochemotherapy. This first population pharmacokinetic analysis of pazopanib shows that inter-individual and inter-study pharmacokinetic variability emphasize the need for further evaluation of therapeutic drug monitoring for pazopanib as suggested for other tyrosine kinase inhibitors. More... »

PAGES

1189-1196

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-014-2455-3

DOI

http://dx.doi.org/10.1007/s00280-014-2455-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1012606735

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24705975


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Toulouse", 
          "id": "https://www.grid.ac/institutes/grid.11417.32", 
          "name": [
            "EA4553 Institut Claudius-Regaud, Universit\u00e9 de Toulouse, 20, rue du Pont-Saint-Pierre, 31052, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Imbs", 
        "givenName": "Diane-Charlotte", 
        "id": "sg:person.01100736712.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100736712.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Centre L\u00e9on-B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "N\u00e9grier", 
        "givenName": "Sylvie", 
        "id": "sg:person.0723756046.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Centre L\u00e9on-B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cassier", 
        "givenName": "Philippe", 
        "id": "sg:person.01312356242.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312356242.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hollebecque", 
        "givenName": "Antoine", 
        "id": "sg:person.0602246235.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602246235.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Varga", 
        "givenName": "Andrea", 
        "id": "sg:person.0650261376.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650261376.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Centre L\u00e9on-B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blanc", 
        "givenName": "Ellen", 
        "id": "sg:person.01356177754.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356177754.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Toulouse", 
          "id": "https://www.grid.ac/institutes/grid.11417.32", 
          "name": [
            "EA4553 Institut Claudius-Regaud, Universit\u00e9 de Toulouse, 20, rue du Pont-Saint-Pierre, 31052, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lafont", 
        "givenName": "Thierry", 
        "id": "sg:person.0734775610.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734775610.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "Bernard", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soria", 
        "givenName": "Jean-Charles", 
        "id": "sg:person.01225022325.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225022325.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Centre L\u00e9on-B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "P\u00e9rol", 
        "givenName": "David", 
        "id": "sg:person.01221677717.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221677717.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Toulouse", 
          "id": "https://www.grid.ac/institutes/grid.11417.32", 
          "name": [
            "EA4553 Institut Claudius-Regaud, Universit\u00e9 de Toulouse, 20, rue du Pont-Saint-Pierre, 31052, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chatelut", 
        "givenName": "Etienne", 
        "id": "sg:person.01333606250.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333606250.74"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2007.10.8332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000481419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-07-0193", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005286411"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-1734", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009118620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/00498254.2012.734642", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019024553"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/13543784.17.2.253", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020458630"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-014-2374-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022673091", 
          "https://doi.org/10.1007/s00280-014-2374-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-2740", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025063112"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604355", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025845256", 
          "https://doi.org/10.1038/sj.bjc.6604355"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2010.199", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030107256", 
          "https://doi.org/10.1038/clpt.2010.199"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijpharm.2012.05.038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038585804"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14656566.2013.780030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039429450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2010.158", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041054235", 
          "https://doi.org/10.1038/clpt.2010.158"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2010.158", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041054235", 
          "https://doi.org/10.1038/clpt.2010.158"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2010.08.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049508007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.0108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049557004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-007-0664-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049611834", 
          "https://doi.org/10.1007/s00280-007-0664-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-007-0664-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049611834", 
          "https://doi.org/10.1007/s00280-007-0664-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14712598.5.1.s37", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067589555"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14712598.5.1.s37", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067589555"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.15_suppl.3048", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083942927"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-06", 
    "datePublishedReg": "2014-06-01", 
    "description": "A combination of monoclonal antibody that binds and inhibits effects induced by vascular endothelial growth factor and tyrosine kinase inhibitor of vascular endothelial growth factor receptor represents a promising concept to block pathological angiogenesis completely. A phase I study combining daily oral pazopanib and bevacizumab (given iv every 2 weeks) was performed in order to determine the maximum tolerated dose of the two drugs in combination. Pazopanib pharmacokinetics were evaluated to compare pharmacokinetic parameters given alone and those observed on the day of the bevacizumab administration. Plasma pazopanib concentrations were obtained in 25 patients treated at two dose levels (400 or 600 mg) at Day 1 (given alone) and Day 15 (the day of the 7.5 mg/kg bevacizumab infusion), and analyzed using the NONMEM program. The apparent oral clearance (CL/F, mean value of 0.60 L/h) presented an inter-individual variability of 40 %, and an inter-occasion of 27 %. A modest but statistically significant decrease in CL/F was observed from Day 1 to Day 15 (-16.4, 95 % confidence interval of -8.5 to -27.2 %). However, trough pazopanib concentrations observed at Day 16 (24 h after the bevacizumab iv infusion) were not significantly higher than those observed just before the beginning of the bevacizumab iv infusion, suggesting that the pharmacokinetic change between Day 1 and Day 15 was not due to an interaction of bevacizumab. Overall, the mean observed concentrations at the maximum tolerated pazopanib dose (600 mg) at both Day 1 and Day 15 were higher than those observed at 800 mg once daily level (corresponding to the recommended dose when given alone) during the first-in-man phase 1 study of pazopanib in monochemotherapy. This first population pharmacokinetic analysis of pazopanib shows that inter-individual and inter-study pharmacokinetic variability emphasize the need for further evaluation of therapeutic drug monitoring for pazopanib as suggested for other tyrosine kinase inhibitors.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-014-2455-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "73"
      }
    ], 
    "name": "Pharmacokinetics of pazopanib administered in combination with bevacizumab", 
    "pagination": "1189-1196", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3c0fb27ee062e7e082c932c4464b6758593b05bc2cad2abf0901bf42d33334e4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24705975"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-014-2455-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1012606735"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-014-2455-3", 
      "https://app.dimensions.ai/details/publication/pub.1012606735"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000511.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-014-2455-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2455-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2455-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2455-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2455-3'


 

This table displays all metadata directly associated to this object as RDF triples.

261 TRIPLES      21 PREDICATES      61 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-014-2455-3 schema:about N017eb5702b1042d88b088bfe5ab1b835
2 N4c418be414e841f48049af97608b747b
3 N5265e06daa264b48b72790dde0d687de
4 N5406df56338046a08147ae7af466c4a5
5 N64d6382637eb4287a5a43fd1e685decc
6 N7e450c3046a04a0e94888760d46d1b06
7 N84b658292fa24acfbae2046399765917
8 N901aa721783840b7937bf02eeb15db9c
9 N9bc5a474f46e4c798dbd5c9f41bf6677
10 Nac0a2f5ee6fe42feb1c0b5f156883243
11 Nb18b19267fb44db8872cf741d151eea4
12 Nb23499eebd184695ad8afe3bbceb0847
13 Nbfc8e98827904c7bbf20cf184d6c6428
14 Nf5397a39e27e41c69f0e663b99a96902
15 Nff5688a6e1e54bd081697f4491d02c06
16 anzsrc-for:11
17 anzsrc-for:1115
18 schema:author N21222bbb0e894c9a900fca079bfb0222
19 schema:citation sg:pub.10.1007/s00280-007-0664-8
20 sg:pub.10.1007/s00280-014-2374-3
21 sg:pub.10.1038/clpt.2010.158
22 sg:pub.10.1038/clpt.2010.199
23 sg:pub.10.1038/sj.bjc.6604355
24 https://doi.org/10.1016/j.ctrv.2010.08.006
25 https://doi.org/10.1016/j.ijpharm.2012.05.038
26 https://doi.org/10.1158/1078-0432.ccr-08-2740
27 https://doi.org/10.1158/1078-0432.ccr-11-1734
28 https://doi.org/10.1158/1535-7163.mct-07-0193
29 https://doi.org/10.1200/jco.2007.10.8332
30 https://doi.org/10.1200/jco.2008.19.0108
31 https://doi.org/10.1200/jco.2010.28.15_suppl.3048
32 https://doi.org/10.1517/13543784.17.2.253
33 https://doi.org/10.1517/14656566.2013.780030
34 https://doi.org/10.1517/14712598.5.1.s37
35 https://doi.org/10.3109/00498254.2012.734642
36 schema:datePublished 2014-06
37 schema:datePublishedReg 2014-06-01
38 schema:description A combination of monoclonal antibody that binds and inhibits effects induced by vascular endothelial growth factor and tyrosine kinase inhibitor of vascular endothelial growth factor receptor represents a promising concept to block pathological angiogenesis completely. A phase I study combining daily oral pazopanib and bevacizumab (given iv every 2 weeks) was performed in order to determine the maximum tolerated dose of the two drugs in combination. Pazopanib pharmacokinetics were evaluated to compare pharmacokinetic parameters given alone and those observed on the day of the bevacizumab administration. Plasma pazopanib concentrations were obtained in 25 patients treated at two dose levels (400 or 600 mg) at Day 1 (given alone) and Day 15 (the day of the 7.5 mg/kg bevacizumab infusion), and analyzed using the NONMEM program. The apparent oral clearance (CL/F, mean value of 0.60 L/h) presented an inter-individual variability of 40 %, and an inter-occasion of 27 %. A modest but statistically significant decrease in CL/F was observed from Day 1 to Day 15 (-16.4, 95 % confidence interval of -8.5 to -27.2 %). However, trough pazopanib concentrations observed at Day 16 (24 h after the bevacizumab iv infusion) were not significantly higher than those observed just before the beginning of the bevacizumab iv infusion, suggesting that the pharmacokinetic change between Day 1 and Day 15 was not due to an interaction of bevacizumab. Overall, the mean observed concentrations at the maximum tolerated pazopanib dose (600 mg) at both Day 1 and Day 15 were higher than those observed at 800 mg once daily level (corresponding to the recommended dose when given alone) during the first-in-man phase 1 study of pazopanib in monochemotherapy. This first population pharmacokinetic analysis of pazopanib shows that inter-individual and inter-study pharmacokinetic variability emphasize the need for further evaluation of therapeutic drug monitoring for pazopanib as suggested for other tyrosine kinase inhibitors.
39 schema:genre research_article
40 schema:inLanguage en
41 schema:isAccessibleForFree false
42 schema:isPartOf Nc7c97a9223574a278f7e18a7e9257f38
43 Nca660016fa214641bd5d0a9fc74ae8ae
44 sg:journal.1088364
45 schema:name Pharmacokinetics of pazopanib administered in combination with bevacizumab
46 schema:pagination 1189-1196
47 schema:productId N22c64435e1a34d4eafb4c000724c741f
48 N5ada8844827d49069e8ab78dccbe67b6
49 N99b02faf2a2b467ba615a2f432f1cf8d
50 Nae08d52b541d4e4cbad1a59396cd6e5c
51 Neaec66a155f54b8abda40accde1c8ddf
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012606735
53 https://doi.org/10.1007/s00280-014-2455-3
54 schema:sdDatePublished 2019-04-10T19:57
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher Nc0110a84186b47cfa0415428f3fec257
57 schema:url http://link.springer.com/10.1007%2Fs00280-014-2455-3
58 sgo:license sg:explorer/license/
59 sgo:sdDataset articles
60 rdf:type schema:ScholarlyArticle
61 N017eb5702b1042d88b088bfe5ab1b835 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Middle Aged
63 rdf:type schema:DefinedTerm
64 N155798c2c8664b41b1bb1060d643bcfe rdf:first sg:person.0723756046.31
65 rdf:rest N6d60931a8bed47eeab1a49283a1f887b
66 N21222bbb0e894c9a900fca079bfb0222 rdf:first sg:person.01100736712.19
67 rdf:rest N155798c2c8664b41b1bb1060d643bcfe
68 N22c64435e1a34d4eafb4c000724c741f schema:name readcube_id
69 schema:value 3c0fb27ee062e7e082c932c4464b6758593b05bc2cad2abf0901bf42d33334e4
70 rdf:type schema:PropertyValue
71 N3549e580994f4402b4a001ed7303be01 rdf:first sg:person.0734775610.77
72 rdf:rest N7d9daf5fcffd4e87beff9b20db24d2d3
73 N35c30b726b15483a9e1a589e5d63544e rdf:first sg:person.01225022325.73
74 rdf:rest Nad06f862b70e49eea8508c0556e09c83
75 N49c635ab570140728a1a14131cc11837 rdf:first sg:person.01356177754.57
76 rdf:rest N3549e580994f4402b4a001ed7303be01
77 N4c418be414e841f48049af97608b747b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Antineoplastic Combined Chemotherapy Protocols
79 rdf:type schema:DefinedTerm
80 N4db740206c16451d9c42d32fa2627b72 rdf:first sg:person.0650261376.19
81 rdf:rest N49c635ab570140728a1a14131cc11837
82 N5265e06daa264b48b72790dde0d687de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Male
84 rdf:type schema:DefinedTerm
85 N5406df56338046a08147ae7af466c4a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Protein Kinase Inhibitors
87 rdf:type schema:DefinedTerm
88 N5ada8844827d49069e8ab78dccbe67b6 schema:name nlm_unique_id
89 schema:value 7806519
90 rdf:type schema:PropertyValue
91 N64d6382637eb4287a5a43fd1e685decc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Pyrimidines
93 rdf:type schema:DefinedTerm
94 N6d60931a8bed47eeab1a49283a1f887b rdf:first sg:person.01312356242.78
95 rdf:rest Nd99e6737c4b14f13b594dc6a9700d9f8
96 N7d9daf5fcffd4e87beff9b20db24d2d3 rdf:first sg:person.01304252172.82
97 rdf:rest N35c30b726b15483a9e1a589e5d63544e
98 N7e450c3046a04a0e94888760d46d1b06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Antibodies, Monoclonal, Humanized
100 rdf:type schema:DefinedTerm
101 N84b658292fa24acfbae2046399765917 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Female
103 rdf:type schema:DefinedTerm
104 N901aa721783840b7937bf02eeb15db9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Kidney Neoplasms
106 rdf:type schema:DefinedTerm
107 N99b02faf2a2b467ba615a2f432f1cf8d schema:name pubmed_id
108 schema:value 24705975
109 rdf:type schema:PropertyValue
110 N9bc5a474f46e4c798dbd5c9f41bf6677 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Aged
112 rdf:type schema:DefinedTerm
113 Nac0a2f5ee6fe42feb1c0b5f156883243 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Sulfonamides
115 rdf:type schema:DefinedTerm
116 Nad06f862b70e49eea8508c0556e09c83 rdf:first sg:person.01221677717.00
117 rdf:rest Nfcfc8323bdc941258ce464544520f1db
118 Nae08d52b541d4e4cbad1a59396cd6e5c schema:name doi
119 schema:value 10.1007/s00280-014-2455-3
120 rdf:type schema:PropertyValue
121 Nb18b19267fb44db8872cf741d151eea4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Bevacizumab
123 rdf:type schema:DefinedTerm
124 Nb23499eebd184695ad8afe3bbceb0847 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Drug Interactions
126 rdf:type schema:DefinedTerm
127 Nbfc8e98827904c7bbf20cf184d6c6428 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Carcinoma, Renal Cell
129 rdf:type schema:DefinedTerm
130 Nc0110a84186b47cfa0415428f3fec257 schema:name Springer Nature - SN SciGraph project
131 rdf:type schema:Organization
132 Nc7c97a9223574a278f7e18a7e9257f38 schema:issueNumber 6
133 rdf:type schema:PublicationIssue
134 Nca660016fa214641bd5d0a9fc74ae8ae schema:volumeNumber 73
135 rdf:type schema:PublicationVolume
136 Nd99e6737c4b14f13b594dc6a9700d9f8 rdf:first sg:person.0602246235.37
137 rdf:rest N4db740206c16451d9c42d32fa2627b72
138 Neaec66a155f54b8abda40accde1c8ddf schema:name dimensions_id
139 schema:value pub.1012606735
140 rdf:type schema:PropertyValue
141 Nf5397a39e27e41c69f0e663b99a96902 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 Nfcfc8323bdc941258ce464544520f1db rdf:first sg:person.01333606250.74
145 rdf:rest rdf:nil
146 Nff5688a6e1e54bd081697f4491d02c06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Adult
148 rdf:type schema:DefinedTerm
149 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
150 schema:name Medical and Health Sciences
151 rdf:type schema:DefinedTerm
152 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
153 schema:name Pharmacology and Pharmaceutical Sciences
154 rdf:type schema:DefinedTerm
155 sg:journal.1088364 schema:issn 0344-5704
156 1432-0843
157 schema:name Cancer Chemotherapy and Pharmacology
158 rdf:type schema:Periodical
159 sg:person.01100736712.19 schema:affiliation https://www.grid.ac/institutes/grid.11417.32
160 schema:familyName Imbs
161 schema:givenName Diane-Charlotte
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100736712.19
163 rdf:type schema:Person
164 sg:person.01221677717.00 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
165 schema:familyName Pérol
166 schema:givenName David
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221677717.00
168 rdf:type schema:Person
169 sg:person.01225022325.73 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
170 schema:familyName Soria
171 schema:givenName Jean-Charles
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225022325.73
173 rdf:type schema:Person
174 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
175 schema:familyName Escudier
176 schema:givenName Bernard
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
178 rdf:type schema:Person
179 sg:person.01312356242.78 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
180 schema:familyName Cassier
181 schema:givenName Philippe
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312356242.78
183 rdf:type schema:Person
184 sg:person.01333606250.74 schema:affiliation https://www.grid.ac/institutes/grid.11417.32
185 schema:familyName Chatelut
186 schema:givenName Etienne
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333606250.74
188 rdf:type schema:Person
189 sg:person.01356177754.57 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
190 schema:familyName Blanc
191 schema:givenName Ellen
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356177754.57
193 rdf:type schema:Person
194 sg:person.0602246235.37 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
195 schema:familyName Hollebecque
196 schema:givenName Antoine
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602246235.37
198 rdf:type schema:Person
199 sg:person.0650261376.19 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
200 schema:familyName Varga
201 schema:givenName Andrea
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650261376.19
203 rdf:type schema:Person
204 sg:person.0723756046.31 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
205 schema:familyName Négrier
206 schema:givenName Sylvie
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31
208 rdf:type schema:Person
209 sg:person.0734775610.77 schema:affiliation https://www.grid.ac/institutes/grid.11417.32
210 schema:familyName Lafont
211 schema:givenName Thierry
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734775610.77
213 rdf:type schema:Person
214 sg:pub.10.1007/s00280-007-0664-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049611834
215 https://doi.org/10.1007/s00280-007-0664-8
216 rdf:type schema:CreativeWork
217 sg:pub.10.1007/s00280-014-2374-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022673091
218 https://doi.org/10.1007/s00280-014-2374-3
219 rdf:type schema:CreativeWork
220 sg:pub.10.1038/clpt.2010.158 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041054235
221 https://doi.org/10.1038/clpt.2010.158
222 rdf:type schema:CreativeWork
223 sg:pub.10.1038/clpt.2010.199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030107256
224 https://doi.org/10.1038/clpt.2010.199
225 rdf:type schema:CreativeWork
226 sg:pub.10.1038/sj.bjc.6604355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025845256
227 https://doi.org/10.1038/sj.bjc.6604355
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1016/j.ctrv.2010.08.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049508007
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1016/j.ijpharm.2012.05.038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038585804
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1158/1078-0432.ccr-08-2740 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025063112
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1158/1078-0432.ccr-11-1734 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009118620
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1158/1535-7163.mct-07-0193 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005286411
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1200/jco.2007.10.8332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000481419
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1200/jco.2008.19.0108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049557004
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1200/jco.2010.28.15_suppl.3048 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083942927
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1517/13543784.17.2.253 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020458630
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1517/14656566.2013.780030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039429450
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1517/14712598.5.1.s37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067589555
250 rdf:type schema:CreativeWork
251 https://doi.org/10.3109/00498254.2012.734642 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019024553
252 rdf:type schema:CreativeWork
253 https://www.grid.ac/institutes/grid.11417.32 schema:alternateName University of Toulouse
254 schema:name EA4553 Institut Claudius-Regaud, Université de Toulouse, 20, rue du Pont-Saint-Pierre, 31052, Toulouse, France
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
257 schema:name Institut Gustave Roussy, Villejuif, France
258 rdf:type schema:Organization
259 https://www.grid.ac/institutes/grid.418116.b schema:alternateName Centre Léon Bérard
260 schema:name Centre Léon-Bérard, Lyon, France
261 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...